|Bid||39.33 x 1500|
|Ask||39.35 x 8800|
|Day's range||38.94 - 39.88|
|52-week range||38.09 - 101.90|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
MorphoSys AG Unsponsored ADR (MOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous11.10.2021 / 08:47 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, October 11, 2021MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) received Breakthrough Therapy Designation by the U.S. Food and Drug Admin
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.